Ember Therapeutics Expands Scientific Leadership to Advance Metabolic Pipeline
5/30/2012 9:56:52 AM
BOSTON--(BUSINESS WIRE)--Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the appointment of Jasbir Seehra, Ph.D., to chief scientific officer; also, Jeff Saunders, Ph.D., joins Ember as vice president, small molecule drug discovery. Drs. Seehra and Saunders will advance the company’s work in translating its world-class biology into a proprietary pipeline of groundbreaking therapies for metabolic diseases, including Type 2 diabetes and obesity.
comments powered by